Published in Hematology Week, August 20th, 2007
The SPA is an "agreement" between INNOVIVE and the FDA on the pivotal Phase II study of Tamibarotene, including the study design, the endpoints of the study, and the data analysis. The SPA is intended to provide assurance that if pre-specified trial results are achieved, they may serve as the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.